Imagine being told your child desperately needs a life-changing medication, only to have insurance slam the door shut—twice. This is the heartbreaking reality for countless families, but one North Carolina family refused to accept 'no' as the final answer. Their story highlights a little-known lifeline buried within the Affordable Care Act, a provision that empowers families to fight back against insurance denials. But here's where it gets controversial: while this external review process exists, it's often shrouded in secrecy, leaving many families in the dark about their options. And this is the part most people miss: it's not a guaranteed win. The success rate varies wildly from state to state, leaving families in a frustrating limbo.
In December 2025, Paxton Pope, a 13-year-old from Davidson, North Carolina, found himself at the center of this battle. Paxton suffers from a rare genetic condition caused by a mutation in the SLC6A1 gene, leading to frequent seizures, developmental delays, and movement disorders. His doctor prescribed Ravicti, a drug not specifically approved for his condition but showing promise in reducing seizures linked to the SLC6A1 gene. The cost? A staggering $800,000 per year.
Insurance denied the request—twice. Paxton's parents, Maggie and Greyson Pope, were devastated. They feared Paxton's seizures would worsen, robbing him of his cognitive abilities and, ultimately, his life. 'Every time I saw a seizure, a little piece of my heart would break,' Maggie recalled. 'It’s debilitating to watch someone you love come in and out of cognition and reality.'
But then they discovered a glimmer of hope: a provision in the Affordable Care Act allowing them to request an external review by a state-run panel. This panel, independent of the insurance company, would assign a doctor to review the case and issue a binding decision. The Popes seized this opportunity, submitting paperwork detailing Paxton's condition, the denied claims, and medical test results.
The process wasn't easy. It required persistence, patience, and navigating a complex bureaucratic system. 'If you’re a regular person trying to navigate this process, it’s often really overwhelming and challenging,' said Michele Johnson, executive director of the Tennessee Justice Center. Yet, the Popes persevered. In August 2025, they received the news they'd been praying for: the denial was overturned.
Since gaining access to Ravicti, Paxton's life has transformed. His seizures have plummeted from 12 per hour to about eight per day. He's regaining lost skills, engaging in conversations, and even joining his school's flag football team. 'I was just over the moon,' Maggie said. 'I looked over at him, and he was just smiling.'
The Popes' story is a testament to the power of advocacy and the importance of knowing your rights. But it also exposes the flaws in our healthcare system. Why should families have to fight so hard for essential treatments? Why is this external review process so obscure?
Every state has an insurance department or commission that can assist with external reviews, yet most people remain unaware of their existence. Experts estimate that millions of Americans face denied claims each year, with a 2023 KFF survey revealing that 58% of insured adults have experienced problems using their health insurance, including denied claims. The Commonwealth Fund further highlights that nearly half of Americans received medical bills in 2023 that should have been covered.
The success rate of external reviews varies dramatically. North Carolina's Smart NC program overturned 53% of cases in 2025, while Washington state's rate was a mere 25% in 2024. This inconsistency raises questions about fairness and accessibility.
Is the external review process a true safety net, or just another hurdle for desperate families? Share your thoughts in the comments. If you're facing similar challenges with insurance denials, whether for health, home, or auto, email us at Costofdenial@nbcuni.com. Let’s shed light on these hidden lifelines and demand a system that prioritizes patient needs over corporate profits.
